Literature DB >> 1371491

Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.

J Andersson1, S Nagy, C G Groth, U Andersson.   

Abstract

Mononuclear cells obtained from human blood were mitogen or antigen activated in vitro in the presence or absence of FK506 or cyclosporin A (CsA). Cytokine production was studied at a single-cell level by ultraviolet (UV) microscopy of fixed permeabilized cells using cytokine-specific monoclonal antibodies (mAb). Phenotypic characterization of the monokine-producing cells was achieved by two-colour immunofluorescent staining. Cytokine production after antigen activation with Staphylococcus aureus enterotoxin A (SEA) was significantly reduced. FK506 or CsA inhibited SEA-induced tumour necrosis factor-alpha (TNF-alpha) production both in monocytes (P less than 0.01) and in lymphocytes (P less than 0.001), at a drug concentration of 1-25 ng/ml for FK506 and 100-500 ng/ml for CsA. Lymphocyte synthesis of interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and TNF-beta after SEA activation was also significantly reduced by either of the drugs. In contrast, endotoxin-induced monokine production (TNF-alpha and IL-6) after lipopolysaccharide (LPS) stimulation was unaffected by FK506 or CsA even when added in concentrations as high as 1000 ng/ml. When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha. The 50% inhibitory concentration (IC50) for FK506 or CsA on the cellular synthesis of the various cytokines varied between 0.6 and 1.0 ng/ml and 20 and 60 ng/ml, respectively. Further stimulation by addition of anti-CD28 mAb to the cultures resulted in an augmented IL-2 and IFN-gamma production which was resistant to both FK506 and CsA. This report delineates extensive similarities between the two drugs in mechanisms of immunosuppression by blockade of identical interleukin production. Depending on the mode of cell activation the two drugs inhibited not only cytokine production in lymphocytes but also antigen-induced monokine (TNF-alpha) production in macrophages, although the optimal immunomodulatory effect of FK506 was achieved at a concentration approximately 50-fold lower than that of CsA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371491      PMCID: PMC1384815     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation.

Authors:  J Wu; M A Palladino; I S Figari; R E Morris
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Probing immunosuppressant action with a nonnatural immunophilin ligand.

Authors:  B E Bierer; P K Somers; T J Wandless; S J Burakoff; S L Schreiber
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

3.  T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506.

Authors:  J E Kay; C R Benzie
Journal:  Immunol Lett       Date:  1989-12       Impact factor: 3.685

4.  Receptor-directed focusing of lymphokine release by helper T cells.

Authors:  W J Poo; L Conrad; C A Janeway
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

5.  Effects of a novel immunosuppressive agent, FK506, on human B cell activation.

Authors:  N Suzuki; T Sakane; T Tsunematsu
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

6.  FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes.

Authors:  C S Lin; R C Boltz; J J Siekierka; N H Sigal
Journal:  Cell Immunol       Date:  1991-04-01       Impact factor: 4.868

7.  Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.

Authors:  L S Wicker; R C Boltz; V Matt; E A Nichols; L B Peterson; N H Sigal
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

8.  The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation.

Authors:  B E Bierer; S L Schreiber; S J Burakoff
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

9.  Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells.

Authors:  L P Svedersky; G E Nedwin; D V Goeddel; M A Palladino
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

10.  The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.

Authors:  P S Mattila; K S Ullman; S Fiering; E A Emmel; M McCutcheon; G R Crabtree; L A Herzenberg
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  32 in total

1.  Intracellular cytokines in blood T cells in lung transplant patients--a more relevant indicator of immunosuppression than drug levels.

Authors:  G Hodge; S Hodge; P Reynolds; M Holmes
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

2.  Evaluation of traditional medicines III: the mechanism of immune modulation by PHELA.

Authors:  Makhotso Lekhooa; Andrew Walubo; Jan J B Du Plessis; Motlalepula G Matsabisa
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-02-13

3.  Anti-ulcer effect of FK 506, immunosuppressive agent, in rats.

Authors:  A Zeniya; M Otaka; T Kuwabara; S Fujimori; S Otani; O Masamune
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

Review 4.  Flow cytometry applications in pharmacodynamics and drug delivery.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

5.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

6.  The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction.

Authors:  A Salerno; C T Bonanno; N Caccamo; D Cigna; R Dominici; C Ferro; G Sireci; F Dieli
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

7.  Uroepithelial cells are part of a mucosal cytokine network.

Authors:  S Hedges; W Agace; M Svensson; A C Sjögren; M Ceska; C Svanborg
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

9.  Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.

Authors:  J Van Wauwe; F Aerts; H Walter; M de Boer
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

10.  FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system.

Authors:  Y Elitsur; X Liu; J Dosescu; J A Moshier
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.